Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis C

Free Subscription Articles published in J Viral Hepat Retrieve available abstracts of 202 articles: HTML format

Single Articles

November 2023
1. O'SULLIVAN M, Jones AM, Mourad A, Haddadin Y, et al
   Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
   J Viral Hepat. 2023 Nov 28. doi: 10.1111/jvh.13897.
   PubMed     Abstract available
   
   
   
2. HAJARIZADEH B, Carson JM, Byrne M, Grebely J, et al
   Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
   J Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895.
   PubMed     Abstract available
   
   
   
3. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
   "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
   J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
   PubMed     Abstract available
   
   
   October 2023
4. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
   Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
   J Viral Hepat. 2023 Oct 7. doi: 10.1111/jvh.13892.
   PubMed    
   
   
   September 2023
5. EVANS KN, Vettese T, Wortley PM, Gandhi AP, et al
   HIV and HCV testing at clinical encounters among people who inject drugs, 2013-2018-Opportunities for increased testing and prevention.
   J Viral Hepat. 2023 Sep 19. doi: 10.1111/jvh.13877.
   PubMed     Abstract available
   
   
   
6. CAROLINE A, Kate M, Roberts M, Ryan J, et al
   What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
   J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13888.
   PubMed     Abstract available
   
   
   
7. JOHNSON A, Shearer J, Thompson C, Jelley R, et al
   Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
   J Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887.
   PubMed     Abstract available
   
   
   August 2023
8. BLACH S, Bregenzer A, Bruggmann P, Cerny A, et al
   Assessing the hepatitis C epidemiology in Switzerland: it's not that trivial.
   J Viral Hepat. 2023 Aug 8. doi: 10.1111/jvh.13879.
   PubMed    
   
   
   July 2023
9. PERAZZO H, Castro R, Villela-Nogueira C, Torres M, et al
   Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis.
   J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13876.
   PubMed     Abstract available
   
   
   
10. TORRES C, Bauer G, Aubriet S, Scholtes C, et al
    Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019-2021): A case-control study.
    J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13875.
    PubMed     Abstract available
    
    
    
11. ROSSOTTI R
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
    J Viral Hepat. 2023 Jul 11. doi: 10.1111/jvh.13871.
    PubMed    
    
    
    
12. LU M, Salgia R, Li J, Trudeau S, et al
    Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
    J Viral Hepat. 2023 Jul 6. doi: 10.1111/jvh.13859.
    PubMed     Abstract available
    
    
    June 2023
13. COYLE CR, Desjardins MR, Curriero FC, Rudolph J, et al
    Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.
    J Viral Hepat. 2023 Jun 29. doi: 10.1111/jvh.13864.
    PubMed     Abstract available
    
    
    
14. GORDON SC, Kaushik A, Chastek B, Anderson A, et al
    Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus.
    J Viral Hepat. 2023 Jun 28. doi: 10.1111/jvh.13860.
    PubMed     Abstract available
    
    
    
15. BARRE T, Zucman D, Marcellin F, Ramier C, et al
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2023 Jun 26. doi: 10.1111/jvh.13865.
    PubMed    
    
    
    
16. TRICKEY A, Ingle SM, Boyd A, Gill MJ, et al
    Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
    J Viral Hepat. 2023 Jun 20. doi: 10.1111/jvh.13863.
    PubMed     Abstract available
    
    
    
17. HOVAGUIMIAN F, Beeler PE, Mullhaupt B, Gunthard HF, et al
    Mortality and morbidity related to hepatitis C virus infection in hospitalized adults-A propensity score matched analysis.
    J Viral Hepat. 2023 Jun 12. doi: 10.1111/jvh.13861.
    PubMed     Abstract available
    
    
    
18. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
    Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
    J Viral Hepat. 2023 Jun 6. doi: 10.1111/jvh.13842.
    PubMed     Abstract available
    
    
    
19. DE A, Charak S, Bhagat N, Rathi S, et al
    Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
    J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13844.
    PubMed     Abstract available
    
    
    May 2023
20. JACOBSON IM, Bourgeois S, Mathurin P, Thuluvath P, et al
    The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
    J Viral Hepat. 2023;30:448-454.
    PubMed     Abstract available
    
    
    April 2023
21. PASSOS-CASTILHO AM, Murphy DG, Blouin K, Benedetti A, et al
    A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada.
    J Viral Hepat. 2023 Apr 18. doi: 10.1111/jvh.13837.
    PubMed     Abstract available
    
    
    March 2023
22. HIBBERT M, Simmons R, Harris H, Desai M, et al
    Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
    J Viral Hepat. 2023 Mar 17. doi: 10.1111/jvh.13835.
    PubMed     Abstract available
    
    
    
23. MOREAU C, Roux M, Riou J, Canivet CM, et al
    Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
    J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
    PubMed     Abstract available
    
    
    
24. QIU L, Xu S, Qiu Y, Liu Y, et al
    Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
    PubMed     Abstract available
    
    
    
25. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
    Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
    PubMed     Abstract available
    
    
    
26. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
    Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
    J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
    PubMed     Abstract available
    
    
    February 2023
27. SHAH SHBU, Alavi M, Hajarizadeh B, Matthews G, et al
    Liver-related mortality among people with hepatitis B and C: evaluation of definitions based on linked healthcare administrative datasets.
    J Viral Hepat. 2023 Feb 27. doi: 10.1111/jvh.13824.
    PubMed     Abstract available
    
    
    
28. ZHOU Y, Zhao B, Shi W, Ding X, et al
    The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: a comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13820.
    PubMed     Abstract available
    
    
    
29. ROSSOTTI R, Merli M, Baiguera C, Bana NB, et al
    Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    J Viral Hepat. 2023 Feb 11. doi: 10.1111/jvh.13818.
    PubMed     Abstract available
    
    
    January 2023
30. TERRAULT NA, Slepin J, Kanner R, Gailloux K, et al
    Strategies to Increase Primary Care Provider Capacity for Hepatitis C Care: The California ECHO-PLUS Study.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13807.
    PubMed     Abstract available
    
    
    
31. HUDSON-BUHAGIAR J, Carson J, Monaghan S, Collie P, et al
    Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: a national real-world cohort (REACH-C).
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13803.
    PubMed     Abstract available
    
    
    
32. MOONEYHAN E, Qureshi H, Mahmood H, Tariq M, et al
    Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13802.
    PubMed     Abstract available
    
    
    
33. MCKEEVER A, O'Donovan D, Kee F
    Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community - a Summary Scoping Review.
    J Viral Hepat. 2023 Jan 12. doi: 10.1111/jvh.13801.
    PubMed     Abstract available
    
    
    
34. DEBETTE-GRATIEN M, Francois S, Chevalier C, Alain S, et al
    Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.
    J Viral Hepat. 2023 Jan 3. doi: 10.1111/jvh.13798.
    PubMed     Abstract available
    
    
    December 2022
35. KOZUKA R, Tamori A, Enomoto M, Muto-Yukawa Y, et al
    Risk Factors for Liver-Related and Non-Liver-Related Mortality following a Sustained Virological Response after Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in a Real-World Cohort.
    J Viral Hepat. 2022 Dec 30. doi: 10.1111/jvh.13795.
    PubMed     Abstract available
    
    
    
36. UCHIDA T, Yuji T, Imamura M, Abe-Chayama H, et al
    A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system.
    J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793.
    PubMed     Abstract available
    
    
    
37. YOUSAFZAI MT, Alavi M, Valerio H, Hajarizadeh B, et al
    Hepatitis C care cascade before and during the direct acting antiviral eras in New South Wales, Australia: a population-based linkage study.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13791.
    PubMed     Abstract available
    
    
    
38. SIEGELE-BROWN C, Siegele-Brown M, Cook C, Khakoo SI, et al
    Testing to sustain Hepatitis C elimination targets in people who inject drugs: a network-based model.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13786.
    PubMed     Abstract available
    
    
    
39. LAM L, Fontaine H, Lapidus N, Bellet J, et al
    Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13788.
    PubMed     Abstract available
    
    
    
40. SARACCO M, Tandoi F, Maletta F, Balagna R, et al
    Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.
    J Viral Hepat. 2022 Dec 7. doi: 10.1111/jvh.13782.
    PubMed     Abstract available
    
    
    
41. ROHRIG AM, Jakobi K, Dietz J, Thomas D, et al
    The Role of Serum Sphingolipids as potential biomarkers of non-response to Direct Acting Antiviral-Therapy in Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Dec 4. doi: 10.1111/jvh.13776.
    PubMed     Abstract available
    
    
    
42. GREENWALD ZR, Bouck Z, McLean E, Mason K, et al
    Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: a cross-sectional analysis.
    J Viral Hepat. 2022 Dec 3. doi: 10.1111/jvh.13780.
    PubMed     Abstract available
    
    
    
43. ABDELHAMED W, El-Kassas M
    Hepatocellular Carcinoma and Hepatitis C Virus Treatments: The Bold and The Beautiful.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13778.
    PubMed     Abstract available
    
    
    
44. FELD JJ, Forns X, Dylla DE, Kumada H, et al
    Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
    J Viral Hepat. 2022;29:1050-1061.
    PubMed     Abstract available
    
    
    November 2022
45. HYDE Z, Roura R, Signer D, Patel A, et al
    Evaluation of a Pilot Emergency Department Linkage to Care Program for Patients Previously Diagnosed with Hepatitis C.
    J Viral Hepat. 2022 Nov 28. doi: 10.1111/jvh.13774.
    PubMed     Abstract available
    
    
    
46. PERAZZO H, Silva MST, Coutinho C, Peixoto EM, et al
    Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13771.
    PubMed    
    
    
    October 2022
47. BITTENCOURT PL, Iasi MDSF, Viana MV, Crespo DM, et al
    Poor linkage to care may compromise the brazilian plan for hepatitis c elimination.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13762.
    PubMed     Abstract available
    
    
    
48. CASEY JL, Dore GJ, Grebely J, Matthews GV, et al
    Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761.
    PubMed     Abstract available
    
    
    
49. CHADHA N, Turner A, Sterling RK
    Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13763.
    PubMed     Abstract available
    
    
    
50. HEO M, Pericot-Valverde I, Niu J, Norton BL, et al
    More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL Study.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13756.
    PubMed     Abstract available
    
    
    
51. MENDIZABAL M, Thompson M, Gonzalez-Ballerga E, Anders M, et al
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13758.
    PubMed     Abstract available
    
    
    
52. BRYCE K, Smith C, Rodger A, Macdonald D, et al
    Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13757.
    PubMed     Abstract available
    
    
    September 2022
53. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed     Abstract available
    
    
    
54. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed     Abstract available
    
    
    
55. HARTL L, Jachs M, Bauer D, Simbrunner B, et al
    An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746.
    PubMed     Abstract available
    
    
    
56. REYNOLDS L, Franco R, Prado M, Rodgers JB, et al
    Hepatitis C Active Viremia Over Time in an ED-based Testing Program: Impact, Disparities,.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744.
    PubMed     Abstract available
    
    
    
57. YANG AH, Yardeni D, Hercun J, Kleiner DE, et al
    Shear Wave Elastography: How well does it perform in Chronic Hepatitis D Virus Infection?
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13745.
    PubMed     Abstract available
    
    
    August 2022
58. YOUNOSSI ZM, Yu ML, El-Kassas M, Esmat G, et al
    Severe Impairment of Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Seen in Real-World Practices Across the World: Data from the Global Liver Registry.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13741.
    PubMed     Abstract available
    
    
    
59. MARTIN M, Roth PJ, Niu J, Pericot-Valverde I, et al
    Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
    J Viral Hepat. 2022 Aug 23. doi: 10.1111/jvh.13737.
    PubMed     Abstract available
    
    
    
60. BARRANCO MA, Rosenberg ES, Flanigan C, Shufelt S, et al
    A cross-sectional study of Hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    J Viral Hepat. 2022 Aug 4. doi: 10.1111/jvh.13735.
    PubMed     Abstract available
    
    
    July 2022
61. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed     Abstract available
    
    
    
62. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed     Abstract available
    
    
    June 2022
63. FACTOR SH, Fierer DS
    Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13726.
    PubMed    
    
    
    
64. TRAEGER MW, van Santen DK, Sacks-Davis R, Asselin J, et al
    Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13723.
    PubMed     Abstract available
    
    
    
65. SHIHA G, Soliman R, Mikhail NNH, Carrat F, et al
    International Multicenter Validation of GES score for HCC risk stratification in chronic hepatitis C patients.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13717.
    PubMed     Abstract available
    
    
    
66. EVON DM, Dong M, Reeve BB, Peter J, et al
    Sustainable and Equivalent Improvements in Symptoms and Functional Well-Being Following Viral Cure from Ledipasvir/Sofosbuvir versus Elbasvir/Grazoprevir for Chronic Hepatitis C Infection: Findings from the randomized PRIORITIZE trial.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13716.
    PubMed     Abstract available
    
    
    
67. HSU WF, Lai HC, Chuang PH, Su WP, et al
    Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13715.
    PubMed     Abstract available
    
    
    
68. ROBINS A, Dolman G, Williams S, Gelson W, et al
    Hepatitis E Case Series. A UK Experience.
    J Viral Hepat. 2022 Jun 2. doi: 10.1111/jvh.13714.
    PubMed     Abstract available
    
    
    May 2022
69. ASKAR S, Jelley R, McQue K, Allsop C, et al
    Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
    PubMed     Abstract available
    
    
    
70. RAMOS-RINCON JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchon C, et al
    Hepatitis C Hospitalizations in Spain and Impact of New Curative Antiviral Therapies.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13708.
    PubMed     Abstract available
    
    
    
71. MARLEY G, Seto WK, Yan W, Chan P, et al
    What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13711.
    PubMed     Abstract available
    
    
    
72. PRINSENBERG T, Schinkel J, Zantkuijl P, Davidovich U, et al
    Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13706.
    PubMed     Abstract available
    
    
    
73. CARSON JM, Hajarizadeh B, Hanson J, O'Beirne J, et al
    Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13705.
    PubMed     Abstract available
    
    
    
74. ZHENG K, Xia T, Liu N, Xia X, et al
    MicroRNA-206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signaling pathway.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13703.
    PubMed     Abstract available
    
    
    
75. BEER L, Inglis S, Malaguti A, Byrne C, et al
    Randomised Clinical Trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13701.
    PubMed     Abstract available
    
    
    
76. VARGAS-ACCARINO E, Martinez-Camprecios J, Dominguez-Hernandez R, Rando-Segura A, et al
    Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13686.
    PubMed     Abstract available
    
    
    
77. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Live
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13684.
    PubMed     Abstract available
    
    
    
78. JONES AT, Briones C, Tran T, Moreno-Walton L, et al
    Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685.
    PubMed     Abstract available
    
    
    
79. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13681.
    PubMed     Abstract available
    
    
    March 2022
80. LEE J, Ahn SB, Yim SY, An J, et al
    Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (>/= 65 years old): A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13679.
    PubMed     Abstract available
    
    
    
81. TERGAST TL, Blach S, Tacke F, Berg T, et al
    Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13680.
    PubMed     Abstract available
    
    
    
82. HASSAN A, Agustin HGS, Burke L, Kofron R, et al
    Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13678.
    PubMed     Abstract available
    
    
    
83. WARD E, Carlisle N, Williams E, Heath SL, et al
    Prevalence of Hepatitis C in Sexual Assault Survivors Presenting to a SANE Clinic: A Descriptive Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675.
    PubMed     Abstract available
    
    
    
84. OZGA JE, Syvertsen JL, Pollini RA
    Hepatitis C Antibody Prevalence, Correlates, and Barriers to Care among People Who Inject Drugs in Central California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13677.
    PubMed     Abstract available
    
    
    
85. NEBBIA G, Ruf M, Hunter L, Balasegaram S, et al
    The VirA+EmiC project - Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13676.
    PubMed     Abstract available
    
    
    
86. KRINGS A, Schmidt D, Meixenberger K, Bannert N, et al
    Decreasing prevalence and stagnating incidence of Hepatitis C-coinfection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
    J Viral Hepat. 2022 Mar 18. doi: 10.1111/jvh.13670.
    PubMed     Abstract available
    
    
    
87. MORGAN JR, Marsh E, Savinkina A, Shilton S, et al
    Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset.
    J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672.
    PubMed     Abstract available
    
    
    
88. VERACRUZ N, Gish RG, Cheung R, Chitnis AS, et al
    Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13663.
    PubMed     Abstract available
    
    
    
89. HOWELL J, Traeger MW, Williams B, Layton C, et al
    The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664.
    PubMed     Abstract available
    
    
    
90. CHROMY D, Bauer DJM, Simbrunner B, Jachs M, et al
    'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13665.
    PubMed     Abstract available
    
    
    
91. AKIYAMA MJ, Riback L, Nyakowa M, Musyoki H, et al
    Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13662.
    PubMed     Abstract available
    
    
    
92. KAUR H, Dhiman RK, Kulkarni AV, Premkumar M, et al
    Improvement of Chronic HCV infection related Depression, Anxiety, and Neurocognitive performance in persons achieving SVR-12: a Real-world Cohort Study.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13668.
    PubMed     Abstract available
    
    
    
93. NEPHEW LD, Wang Y, Mohamed K, Nichols D, et al
    Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661.
    PubMed     Abstract available
    
    
    February 2022
94. HOSSEINI-HOOSHYAR S, Alavi M, Martinello M, Valerio H, et al
    Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
    J Viral Hepat. 2022 Feb 17. doi: 10.1111/jvh.13658.
    PubMed     Abstract available
    
    
    
95. WU G, Zhou A, Kwon S
    Integrating Hepatitis C Virus Screening of Baby Boomers at a Community Hospital Emergency Department.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13654.
    PubMed     Abstract available
    
    
    
96. KHERA T, Madsen LW, Du Y, Lillevang ST, et al
    Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13652.
    PubMed     Abstract available
    
    
    January 2022
97. HUA R, Kong F, Wen X, Xiong Q, et al
    Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study.
    J Viral Hepat. 2022 Jan 26. doi: 10.1111/jvh.13650.
    PubMed     Abstract available
    
    
    
98. WU S, Yuan H, Fan H, Xu Y, et al
    Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13647.
    PubMed     Abstract available
    
    
    
99. STOCKDALE AJ, Kreuels B, Shawa IT, Meiring JE, et al
    A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13646.
    PubMed     Abstract available
    
    
    
100. IKENAGA H, Uchida-Kobayashi S, Tamori A, Odagiri N, et al
     Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
     J Viral Hepat. 2022;29:52-59.
     PubMed     Abstract available
     
     
     December 2021
101. DJORDJEVIC F, Ryan K, Gunn J, Brener L, et al
     Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
     J Viral Hepat. 2021;28:1738-1743.
     PubMed     Abstract available
     
     
     November 2021
102. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
     Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
     J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
     PubMed     Abstract available
     
     
     
103. MANDEL E, Peci A, Cronin K, Capraru CI, et al
     The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
     J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
     PubMed     Abstract available
     
     
     
104. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
     Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
     J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
     PubMed     Abstract available
     
     
     
105. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
     Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
     J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
     PubMed     Abstract available
     
     
     
106. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
     A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
     J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
     PubMed     Abstract available
     
     
     
107. GANE E, de Ledinghen V, Dylla DE, Rizzardini G, et al
     Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
     J Viral Hepat. 2021;28:1635-1642.
     PubMed     Abstract available
     
     
     October 2021
108. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
     Role of peer support in a hepatitis C elimination program.
     J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
     PubMed     Abstract available
     
     
     
109. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
     Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
     J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
     PubMed     Abstract available
     
     
     September 2021
110. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
     Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
     J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
     PubMed     Abstract available
     
     
     
111. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
     Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
     J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
     PubMed     Abstract available
     
     
     
112. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
     Letter in response: Psychiatrists can treat hepatitis C.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
     PubMed     Abstract available
     
     
     
113. RODER C, Nguyen P, Harvey C, Wardrop M, et al
     Psychiatrists can treat hepatitis C.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
     PubMed     Abstract available
     
     
     
114. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
     Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
     PubMed     Abstract available
     
     
     
115. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
     Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
     J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
     PubMed     Abstract available
     
     
     
116. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
     Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
     J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
     PubMed     Abstract available
     
     
     
117. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
     Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
     J Viral Hepat. 2021;28:1319-1324.
     PubMed     Abstract available
     
     
     August 2021
118. PALMER AY, Chan K, Gold J, Layton C, et al
     A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
     J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
     PubMed     Abstract available
     
     
     
119. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
     Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
     J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
     PubMed     Abstract available
     
     
     
120. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
     Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
     J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
     PubMed     Abstract available
     
     
     
121. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
     Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
     J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
     PubMed     Abstract available
     
     
     
122. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
     The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
     J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
     PubMed     Abstract available
     
     
     July 2021
123. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
     Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
     J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
     PubMed     Abstract available
     
     
     
124. WANG Y, Zhao Z, Zhang H, Lin Q, et al
     Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
     PubMed     Abstract available
     
     
     
125. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
     Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
     PubMed     Abstract available
     
     
     
126. OHKI T, Satov K, Kondo M, Goto E, et al
     Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
     PubMed     Abstract available
     
     
     
127. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
     Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
     J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
     PubMed     Abstract available
     
     
     
128. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
     Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
     J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
     PubMed     Abstract available
     
     
     
129. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
     The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
     J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
     PubMed     Abstract available
     
     
     
130. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
     A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
     J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
     PubMed     Abstract available
     
     
     
131. ERICE A, Varillas-Delgado D, Caballero C
     Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
     J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
     PubMed     Abstract available
     
     
     
132. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
     Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
     J Viral Hepat. 2021;28:982-993.
     PubMed     Abstract available
     
     
     June 2021
133. KIM HP, Edwards A, Reeve BB, Golin CE, et al
     Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
     PubMed     Abstract available
     
     
     
134. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
     Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
     PubMed     Abstract available
     
     
     
135. KANG Q, Xu J, Luo H, Tan N, et al
     Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
     J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
     PubMed     Abstract available
     
     
     May 2021
136. BROWN C, Siegele M, Wright M, Cook C, et al
     Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
     J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
     PubMed     Abstract available
     
     
     
137. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
     Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
     PubMed     Abstract available
     
     
     
138. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
     Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
     PubMed     Abstract available
     
     
     
139. LIU PC, Chan C, Huang YH, Chen YJ, et al
     Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
     PubMed     Abstract available
     
     
     
140. KIM S, Powell J, Naugle J, Ricco M, et al
     Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
     PubMed     Abstract available
     
     
     
141. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
     Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
     PubMed     Abstract available
     
     
     
142. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
     Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
     J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
     PubMed     Abstract available
     
     
     April 2021
143. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
     Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
     J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
     PubMed     Abstract available
     
     
     
144. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
     Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
     J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
     PubMed     Abstract available
     
     
     
145. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
     Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
     PubMed     Abstract available
     
     
     
146. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
     Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
     J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
     PubMed     Abstract available
     
     
     
147. LEE TH, Chan A, Bryan W, Park L, et al
     Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
     J Viral Hepat. 2021;28:630-636.
     PubMed     Abstract available
     
     
     March 2021
148. BUTT AA, Yan P
     Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
     J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
     PubMed     Abstract available
     
     
     
149. LIU CH, Sun HY, Hsieh SM, Liu WC, et al
     Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
     J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
     PubMed     Abstract available
     
     
     
150. BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
     Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
     J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
     PubMed     Abstract available
     
     
     
151. MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
     The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
     J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
     PubMed     Abstract available
     
     
     
152. MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
     Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
     J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
     PubMed     Abstract available
     
     
     
153. JIANG JJ, Shiels MS, O'Brien TR
     Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
     J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
     PubMed     Abstract available
     
     
     
154. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
     Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
     J Viral Hepat. 2021;28:548-557.
     PubMed     Abstract available
     
     
     February 2021
155. BAR N, Levy S, Deutsch L, Leshno M, et al
     Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
     J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
     PubMed     Abstract available
     
     
     
156. BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
     The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
     J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
     PubMed     Abstract available
     
     
     
157. VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
     Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
     J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
     PubMed     Abstract available
     
     
     
158. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
     Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
     J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
     PubMed     Abstract available
     
     
     
159. TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
     Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
     J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
     PubMed     Abstract available
     
     
     
160. FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
     A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
     J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
     PubMed     Abstract available
     
     
     
161. SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
     Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
     J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
     PubMed     Abstract available
     
     
     
162. VERGARA M, Miquel M, Vela E, Cleries M, et al
     Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
     J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
     PubMed     Abstract available
     
     
     
163. KREKULOVA L, Honzak R, Riley LW
     Viral hepatitis C pandemic: challenges and threats to its elimination.
     J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
     PubMed     Abstract available
     
     
     
164. WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
     Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
     J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
     PubMed     Abstract available
     
     
     
165. PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
     Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
     J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
     PubMed     Abstract available
     
     
     January 2021
166. LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
     Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
     J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
     PubMed     Abstract available
     
     
     
167. WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
     Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
     J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
     PubMed     Abstract available
     
     
     
168. SU X, Zhao X, Deng JL, Li SN, et al
     Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
     J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
     PubMed     Abstract available
     
     
     
169. CHEN B, Ma ZH, Xu B, Chang H, et al
     Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
     J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
     PubMed     Abstract available
     
     
     
170. SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
     Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
     J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
     PubMed     Abstract available
     
     
     
171. FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
     Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
     J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
     PubMed     Abstract available
     
     
     December 2020
172. O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
     Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
     J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
     PubMed     Abstract available
     
     
     
173. FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
     High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
     J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
     PubMed     Abstract available
     
     
     
174. GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
     Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
     J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
     PubMed     Abstract available
     
     
     
175. CHAN K, Elsum I, Gold J, Layton C, et al
     Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
     J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
     PubMed     Abstract available
     
     
     November 2020
176. TADA T, Toyoda H, Kumada T, Kurisu A, et al
     Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
     J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
     PubMed     Abstract available
     
     
     
177. WHITELEY D, Speakman E, Elliott L, Davidson K, et al
     Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
     J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
     PubMed     Abstract available
     
     
     
178. RAZAVI H
     The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
     J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
     PubMed     Abstract available
     
     
     
179. WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
     Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
     J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
     PubMed     Abstract available
     
     
     
180. KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
     Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
     J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
     PubMed     Abstract available
     
     
     
181. RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
     Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
     J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
     PubMed     Abstract available
     
     
     
182. KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
     Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
     J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
     PubMed     Abstract available
     
     
     
183. WU D, Hu S, Chen G, Jiao C, et al
     Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
     J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
     PubMed     Abstract available
     
     
     
184. SHEU MJ, Liang FW, Lu TH
     Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
     J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
     PubMed     Abstract available
     
     
     October 2020
185. GALLACHER J, McPherson S
     Progress towards micro-elimination of hepatitis C in the custodial setting.
     J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
     PubMed    
     
     
     
186. FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
     Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
     J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
     PubMed     Abstract available
     
     
     
187. GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
     HIV influences clustering and intracellular replication of hepatitis C virus.
     J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
     PubMed     Abstract available
     
     
     
188. IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
     Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
     J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
     PubMed     Abstract available
     
     
     
189. REYES-URUENA J, Celly A, Moreno S, Majo X, et al
     Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
     J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
     PubMed     Abstract available
     
     
     
190. CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
     Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
     J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
     PubMed     Abstract available
     
     
     
191. LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
     Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
     J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
     PubMed     Abstract available
     
     
     
192. MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
     Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
     J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
     PubMed     Abstract available
     
     
     
193. RAFIQUE S, Zahid S, Ali A, Tariq M, et al
     Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
     J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
     PubMed     Abstract available
     
     
     
194. POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
     Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
     J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
     PubMed     Abstract available
     
     
     September 2020
195. MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
     Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
     J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
     PubMed     Abstract available
     
     
     
196. JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
     Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
     J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
     PubMed     Abstract available
     
     
     June 2020
197. HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
     Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
     J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
     PubMed     Abstract available
     
     
     April 2020
198. HONG CY, Sinn DH, Kang D, Paik SW, et al
     Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
     J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
     PubMed     Abstract available
     
     
     
199. TSENG CW, Wu SF, Chen CY, Ho YC, et al
     Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
     J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
     PubMed     Abstract available
     
     
     March 2020
200. DARVISHIAN M, Wong S, Binka M, Yu A, et al
     Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
     J Viral Hepat. 2020;27:243-260.
     PubMed     Abstract available
     
     
     September 2019
201. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
     Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
     J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
     PubMed     Abstract available
     
     
     July 2019
202. MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
     Hepatitis B and C virus infection and risk of hematological malignancies.
     J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.